In this article, we will discuss the 10 best-performing NASDAQ stocks in 2024.

Market Expectations for the Year-End

Fed’s recent cut has resulted in significant outperformance in the tech sector, signaling a positive sentiment among investors. Tech stocks are thriving in this lower interest rate environment, which has contributed to a broader market rally. The strength of small-cap stocks and cyclical sectors was noticeable even before the reduction, suggesting that market confidence was building. Analysts expect ongoing growth driven by advancements in AI, which continues to be a key theme influencing investor behavior.

The occurrence of rate cuts while markets are at record highs raises important questions about potential volatility. Historically, markets have shown resilience and often continue to rise even when rate cuts occur near market peaks. This suggests that much of the current optimism may already be reflected in stock prices. The recent rate cut is generally viewed as a preventive measure rather than a direct response to economic weakness, which could further enhance consumer confidence and spending.

Towards the end of September, RaeAnn Mitrione, Investment Management Partner at Callan Family Office, appeared in an interview and highlighted significant market developments following the Fed’s unexpectedly larger-than-anticipated rate cut. We covered this in detail in our article on the 7 Cheap Technology Stocks To Buy Right Now, here’s a short excerpt from it:

“…Mitrione emphasized that the market is reacting favorably to lower interest rates, particularly benefiting the tech sector… Pointing at a chart, Mitrione remarked that it is unusual to see rate cuts while markets are at record highs, raising questions about potential volatility ahead. Historically, even when rate cuts occur near market peaks, stocks often continue to rise. Much of this positive sentiment has been priced in due to prior indications of the rate cut. She explained that the economy remains strong, and the rate cut serves as a preventive measure rather than a reaction to economic weakness. This supportive environment could enhance consumer confidence and spending, further improving market performance.”

On September 28, DataTrek Research co-founder, Nick Colas, joined an interview on CNBC to discuss the trading day and highlight that the tech rally will have to wait until year-end. As September ended, the S&P 500 saw a remarkable increase of 20% year-to-date. In light of this performance, market participants began revisiting the post-Fed rate cut playbook following the initial easing. Nick Colas noted that one of the most encouraging aspects of September is that the market has not experienced a decline, which is typically expected during this month known for its volatility. Instead, the S&P had risen by 1.6% so far in September, demonstrating resilience despite some initial choppiness, which is particularly noteworthy given September’s historical reputation for turbulence.

As Colas noted, on the macroeconomic front, positive indicators are emerging. The Atlanta Fed’s GDPNow model has revised its Q3 growth estimate upward to 3.1%, signaling that the economy is performing well. Additionally, gasoline demand has increased by 6% year-over-year, reflecting strong consumer activity. Initial jobless claims reported recently also show a solid performance, falling below the three-year average. These data points support the mid-cycle playbook employed by DataTrek, suggesting that the economy is continuing to progress without any significant cracks or fissures in its foundation.

Despite these positive trends, questions remain about whether the market can sustain its momentum without new positive catalysts. Colas pointed out that historically, price-to-earnings multiples and stock prices tend to rise together as long as there are no major negative catalysts to disrupt the economic recovery. This correlation indicates that investor confidence remains intact and is likely to persist through the remainder of the year. Furthermore, as the market approaches traditionally strong months following elections, there are expectations for a potential old Santa Claus rally in December.

However, with the volatility index elevated at around 17 and geopolitical tensions looming, especially as elections approach, investors are likely to remain cautious. Over the past two years, the NASDAQ 100 has surged approximately 67%, marking a significant recovery since its lows in October two years ago. This performance is substantially above the historical average return of around 25%. Colas emphasized that while such returns are impressive, they do not yet indicate speculative excess; historically, a doubling of the NASDAQ over two years would signal potential trouble for investors.

Looking back further, Colas noted that since peaking before the bear market in November 2021, the NASDAQ 100 has only risen about 20% over three years. This suggests that there may still be room for growth compared to prior bubbles when returns were much more pronounced within shorter time frames.

The ongoing rotation away from technology stocks has been observed recently, with cyclical sectors and financials performing well. Colas believes this trend may continue for now, with a potential resurgence in tech stocks expected closer to November and December as year-end approaches. Investors appear to be favoring cyclical sectors at present, which offer more immediate upside opportunities.

While there are challenges ahead, the current economic indicators suggest a robust environment for continued growth in equities as long as investor confidence remains high and no major negative catalysts emerge to derail progress. Despite a recent rotation away from tech stocks, the market remains resilient, with the potential for a tech resurgence as we approach year-end, setting the stage for a bullish outlook for both tech and the NASDAQ in the coming months.

When optimism about economic conditions or technological advancements rises, tech stocks typically perform well, boosting the NASDAQ. With that understood, we’re here with a list of the 10 best-performing NASDAQ stocks in 2024.

Methodology

We used stock screeners to look for companies listed on NASDAQ that were trading over $10 billion. We then selected the top 10 NASDAQ stocks with the best year-to-date performance and that were also the most popular among elite hedge funds. The stocks are ranked in ascending order of their year-to-date performance.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).

10 Best Performing NASDAQ Stocks in 2024

10. Futu Holdings Ltd. (NASDAQ:FUTU)

Year-to-Date Performance as of October 2: 96.85%

Number of Hedge Fund Holders: 27

Futu Holdings Ltd. (NASDAQ:FUTU) is an international leading online brokerage firm that provides technology-driven wealth management services. It offers investment products, including stocks, bonds, funds, and derivatives, to retail investors primarily in China and Hong Kong. The innovative mobile app and online platform provide users with real-time market data, advanced trading tools, and personalized investment advice.

In the second quarter of 2024, the company added 155,000 new paying customers, which is a 168% increase year-over-year, making a total of 2 million paying customers, up 29%. Hong Kong and Singapore saw most of this growth, contributing significantly to the overall client base. Japan achieved double-digit growth through enhanced product offerings and marketing. Malaysia also performed well, leading all markets in new client acquisition.

Total revenue in Q2 was up 26% from a year-ago period. Brokerage commission and handling charge income was up 45% year-over-year and 27% quarter-over-quarter. The increase was driven by a 69% year-over-year and a 21% quarter-over-quarter growth in total trading volume.

The recent launch of cryptocurrency trading in Hong Kong and Singapore positions it further for growth in these markets. In Japan, management plans to launch NISA savings accounts, mutual funds, and US margin trading shortly. In Malaysia, the company recently introduced ringgit- and US dollar-denominated money market funds, with a Malaysian stock IPO subscription service. In Canada, it added a cash-plus product that allows clients to earn interest on their idle cash.

The company’s strong financial performance, driven by significant client growth and increased asset inflows, positions it for continued success in the market. The expansion of product offerings and geographic reach indicate a promising outlook for future growth.

9. Natera Inc. (NASDAQ:NTRA)

Year-to-Date Performance as of October 2: 103.05%

Number of Hedge Fund Holders: 60

Natera Inc. (NASDAQ:NTRA) is a clinical genetic testing company that specializes in non-invasive, cell-free DNA testing technology, with a focus on women’s health, cancer, and organ health. Its non-invasive prenatal testing (NIPT) is used to screen for chromosomal abnormalities in fetuses, including Down syndrome, Turner syndrome, and Edwards syndrome. It also offers genetic tests for various conditions related to cancer and hereditary diseases.

The company’s cancer screening is used by over 40% of American oncologists, and this adoption rate could increase if the screening is expanded to cover additional cancers. Natera Inc. (NASDAQ:NTRA) is currently conducting trials to evaluate the effectiveness of its screening for gastric and colorectal cancers.

Revenue in the second quarter of this year was $413.35 million, up 58.13% year-over-year. This was driven by record-high volumes and continued ASP growth. Volumes increased by over 23% year-over-year. Despite seasonal challenges, it saw sequential volume growth from Q1 to Q2.

The organ health and oncology segments also performed well. Signatera, its screening product, added 13,000 units sequentially in Q2, surpassing the baseline of 8,000 by 63%. Management anticipates that Signatera could add between 8,000 and 10,000 units going forward.

It enhanced its Prospera Heart Test to improve organ rejection detection and provide a more accurate risk assessment. Additionally, a recent court ruling upheld the company’s injunction against NeoGenomics’ RaDaR MRD assay.

The company’s unique position in the biotechnology market, providing essential blood tests for cancer treatment monitoring, has enabled it to rapidly gain market share and establish a strong competitive advantage. Hence, Natera Inc. (NASDAQ:NTRA) is poised to grow as an industry leader.

Parnassus Growth Equity Fund stated the following regarding Natera, Inc. (NASDAQ:NTRA) in its Q2 2024 investor letter:

“Natera, Inc. (NASDAQ:NTRA), an industry leader in genetic testing, reported favorable financial results for the first quarter of 2024. The company reached cash flow breakeven early and raised full-year guidance. We are optimistic that upcoming catalysts will continue to fuel growth in its women’s health and oncology businesses.”